retatrutide phase 2 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial Retatrutide, a TRIPLE agonist (GLP1,

Lawsuits claim the manufacturer knew or should have known about these risks and failed to adequately warn patients and doctors, forming the basis for failure to warn legal claims

doi: 10.1186/s12933-021-01437-w 87 AbdelrahmanAHSalamaIISalamaSIElmosalamiDMIbrahimMHHassanEMet al

Consider How Long You Need to Be On the GLP1 While effective, weight loss medications are intended to be used as adjuncts to a healthful lifestyle

Clinical experience and patient reports have identified several evidence-based strategies that significantly reduce GLP-1-related nausea

[175] An analysis of events in the US FDA Adverse Event Reporting System suggests an association between several GLP-1 agonists (including semaglutide) and cutaneous reactions, such as dermal hypersensitivity reactions, eosinophilic panniculitis, bullous pemphigoid, and morbilliform drug eruptions